FLUDEOXYGLUCOSE F18

Post-LOE

fludeoxyglucose f 18

Sofie

ANDAINTRAVENOUSINJECTABLE

Approved

Feb 2011

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

FLUDEOXYGLUCOSE F18 (fludeoxyglucose f 18) by Sofie is radiopharmaceutical activity [moa]. Approved for radioactive diagnostic agent [epc]. First approved in 2011.

Drug data last refreshed 1w ago

Mechanism of Action

Radiopharmaceutical Activity

Pharmacologic Class:

Radioactive Diagnostic Agent

Indications (1)

Radioactive Diagnostic Agent

Clinical Trials (1)

NCT00433433Phase 3Unknown

Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma

Started Oct 2006

1,952 enrolled

Lymphoma

Company

Worked on FLUDEOXYGLUCOSE F18 at Sofie? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.